Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

New technologies could aid in malignant melanoma diagnosis and therapy

Because the incidence of malignant melanoma is rising faster than any other cancer in the U.S., researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues at Tampa-based Intezyne Technologies, Inc., Western Carolina University and the University of Arizona are working overtime to develop new technologies to aid in both malignant melanoma diagnosis and therapy.

4 Nov 2011

Using sub-nanometre cages to identify molecules

Reliable and accurate single-molecule medical diagnosis is a step closer to reality with the development a new technique by Cambridge University researchers which uses sub-nanometre “cages” to capture and identify molecules.

3 Nov 2011

Senior Scientific's nanomagnetic technology more sensitive in detecting breast cancer

Manhattan Scientifics announced today that "Breast Cancer Research," an international, peer-reviewed online journal, has published results of a study using Senior Scientific's nanomagnetic technology.

1 Nov 2011

Researchers explore novel therapeutic approach for thyroid cancer

Some forms of differentiated thyroid cancer (DTC) respond to treatment with radioactive iodine, which is taken up by the thyroid gland, destroying the cancerous cells. However patients with two forms of thyroid cancer, radioiodine-refractory DTC and anaplastic thyroid cancer (ATC), do not benefit from radioiodine therapy, and other treatment options are limited.

28 Oct 2011

Arrowhead acquires RNA therapeutics assets from Roche

Arrowhead Research Corporation, today announced that it has acquired RNA therapeutics assets from Roche including the state-of-the-art research site in Madison, WI.

24 Oct 2011

Encap Drug Delivery and Lena Nanoceutics to develop new drug delivery technology

Encap Drug Delivery and Lena Nanoceutics today announce a collaboration agreement to develop a new drug delivery technology (Nano-Capsules) which combines Lena’s proprietary nano-particle engineering technology with Encap’s liquid filled hard capsule technology.

24 Oct 2011

'Lance Armstrong effect' could become powerful new cancer weapon

The "Lance Armstrong effect" could become a powerful new weapon to fight cancer cells that develop resistance to chemotherapy, radiation and other treatments, scientists say in a report in the ACS journal Molecular Pharmaceutics.

20 Oct 2011

First patient treated with MagForce's NanoTherm therapy for recurrent glioblastoma

Nanostart-holding MagForce AG, a leading medical technology company focusing on nanomedicine in oncology, announced today the treatment of a recurrent glioblastoma patient with the company's NanoTherm therapy.

11 Oct 2011

New siRNA treatment reduces damaging inflammation in animals models of several disorders

Massachusetts General Hospital (MGH) researchers - along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals - have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions.

10 Oct 2011

Three Penn labs receive NIH grant to speed translation of medical research into patient care

Three labs from the University of Pennsylvania have received $12.5 million from the National Institutes of Health (NIH) as part of its $143.8 million national grant program to challenge the scientific status quo with innovative ideas that have the potential to speed the translation of medical research into improved health for the American public.

4 Oct 2011

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.

27 Sep 2011

NIDA announces winners of Avant-Garde Awards for Innovative Medication Development Research

Scientists proposing to develop vaccines against methamphetamine and nicotine have been selected to receive NIDA's second Avant-Garde Awards for Innovative Medication Development Research.

22 Sep 2011

NIH-funded project to develop new class of tissue regeneration therapeutics

The National Institutes of Health (NIH) has awarded nearly $2 million to researchers at the Georgia Institute of Technology and Emory University to develop a new class of therapeutics for treating traumatic injuries and degenerative diseases.

22 Sep 2011

UNC's new nanoparticle shows potential for cancer chemotherapy

A new type of nanoparticle developed in the laboratories at the University of North Carolina has shown potential for more effective delivery of chemotherapy to treat cancer.

21 Sep 2011

Preclinical studies shows EmPAC more effective than Taxol

Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone’s proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi’s sarcoma.

19 Sep 2011

Techulon signs distribution agreement with BioConcept for Glycofect

Techulon Inc., the leader in low-toxicity gene delivery has signed a distribution agreement with BioConcept of Allschwil, Switzerland.

19 Sep 2011

Nanoparticles have a detrimental effect on the fish brain

Scientists at the University of Plymouth have shown, for the first time in an animal, that nanoparticles have a detrimental effect on the brain and other parts of the central nervous system.

19 Sep 2011

Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma

Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.

14 Sep 2011

Scientists invent new system that uses magnetism to purify hybrid nanoparticles

A team of Penn State University scientists has invented a new system that uses magnetism to purify hybrid nanoparticles -- structures that are composed of two or more kinds of materials in an extremely small particle that is visible only with an electron microscope.

8 Sep 2011

SAIC awards Selecta a subcontract to develop synthetic nanoparticle vaccine for malaria

Selecta Biosciences, Inc., a biopharmaceutical company developing an entirely new class of targeted vaccines and immunotherapies, today announced that Science Applications International Corporation (SAIC) has awarded Selecta a subcontract to develop a targeted synthetic vaccine particle product for malaria.

31 Aug 2011

Nanoparticle News and Research

Further Reading

New technologies could aid in malignant melanoma diagnosis and therapy

Using sub-nanometre cages to identify molecules

Senior Scientific's nanomagnetic technology more sensitive in detecting breast cancer

Researchers explore novel therapeutic approach for thyroid cancer

Arrowhead acquires RNA therapeutics assets from Roche

Encap Drug Delivery and Lena Nanoceutics to develop new drug delivery technology

'Lance Armstrong effect' could become powerful new cancer weapon

First patient treated with MagForce's NanoTherm therapy for recurrent glioblastoma

New siRNA treatment reduces damaging inflammation in animals models of several disorders

Three Penn labs receive NIH grant to speed translation of medical research into patient care

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

NIDA announces winners of Avant-Garde Awards for Innovative Medication Development Research

NIH-funded project to develop new class of tissue regeneration therapeutics

UNC's new nanoparticle shows potential for cancer chemotherapy

Preclinical studies shows EmPAC more effective than Taxol

Techulon signs distribution agreement with BioConcept for Glycofect

Nanoparticles have a detrimental effect on the fish brain

Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma

Scientists invent new system that uses magnetism to purify hybrid nanoparticles

SAIC awards Selecta a subcontract to develop synthetic nanoparticle vaccine for malaria

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News